Compare SVM & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | SUPN |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2005 | 2010 |
| Metric | SVM | SUPN |
|---|---|---|
| Price | $8.22 | $41.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.50 | ★ $60.50 |
| AVG Volume (30 Days) | ★ 1.8M | 839.6K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $3.19 | $21.56 |
| Revenue Next Year | $74.89 | $55.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.97 | $37.54 |
| 52 Week High | $15.77 | $59.68 |
| Indicator | SVM | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 49.95 |
| Support Level | N/A | $37.54 |
| Resistance Level | $13.53 | $51.59 |
| Average True Range (ATR) | 0.38 | 1.93 |
| MACD | -0.09 | 0.15 |
| Stochastic Oscillator | 2.90 | 61.67 |
Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.